Charting Emerging Markets: J&J Growth Rates
This article was originally published in PharmAsia News
PharmAsia News takes a closer look at J&J’s growth in key emerging markets.
You may also be interested in...
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.